Review
Version 2
Preserved in Portico This version is not peer-reviewed
The human-COVID-19 Tango: Connecting the Dots
Version 1
: Received: 8 April 2020 / Approved: 9 April 2020 / Online: 9 April 2020 (14:48:21 CEST)
Version 2 : Received: 13 April 2020 / Approved: 14 April 2020 / Online: 14 April 2020 (14:34:43 CEST)
Version 2 : Received: 13 April 2020 / Approved: 14 April 2020 / Online: 14 April 2020 (14:34:43 CEST)
How to cite: Hamdi, H.; Abdaldayem, E. The human-COVID-19 Tango: Connecting the Dots. Preprints 2020, 2020040160. https://doi.org/10.20944/preprints202004.0160.v2 Hamdi, H.; Abdaldayem, E. The human-COVID-19 Tango: Connecting the Dots. Preprints 2020, 2020040160. https://doi.org/10.20944/preprints202004.0160.v2
Abstract
As the world grapples with a pandemic with various and expanding epicenters, a flurry of medical and scientific activity has gained speed and momentum in a race to halt COVID-19. A controversial topic has been the connection between COVID-19 and the Renin-Angiotensin system (RAS). COVID-19, like Sars before it, enters by way of the Angiotensin Converting Enzyme 2 (ACE2). ACE2 is ubiquitously expressed in many tissues in the body serving as the doorway by which the virus can enter and spread causing inflammatory havoc. Demographic evidence coming out of China and other locations make it clear that the elderly and those suffering cardiovascular complications such as hypertension etc are most at risk. The connection to RAS and the demographic nature of the data coming out has led many to advance hypothesis, recommendations and even therapies based on existing RAS inhibitors and other components of the renin-Angiotensin system. It is pertinent to review the literature in the context of our understanding of the renin-angiotesnin system to allow better judgements to be made as well as lines of research initiated advancing a quick resolution to COVID-19. Covid-19 appears invincible as if dipped in the river Styx, but even Achilles had a vulnerable heel. Understanding the homeostatic balance that the coronavirus disrupts, we can discover the arrow in corona’s heel.
Keywords
COVID-19; ACE; ACE2; Angiotensin II; Bradykinin; RAS inhibitors; ACE inhibitors; AT1 receptor blockers; Losartan; Bradykinin Antagonists; Ang II loading; Giapreza; Icatibant.
Subject
Biology and Life Sciences, Virology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (2)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: Hamdi Hamdi
Commenter's Conflict of Interests: Author
Commenter: Hawazen Hirbawi
The commenter has declared there is no conflict of interests.
Hawazen Hirbawi, MD
Commenter: Julia Driessen
The commenter has declared there is no conflict of interests.
Thank you for this very interesting review on the interaction of RAS and COVID-19.
Could you comment on the prevalence of COVID19 among young adults without any medical history, who are often athletes, and still can get very ill from COVID19?
Would it be possible that due to high excercise/training, the angiotensin II levels are lower in these people, which would sensitize them for COVID19 due to less competition with the ACE2 receptor?
Many thanks in advance,
Best regards,
Julia Driessen